Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

Get Real-Time News and Alerts for Your Portfolio Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the initial cognitive damage caused by dementia, and explains how it works ...

How Dementia Affects the Brain's ... Huntington's disease (HD), according to a new ... 'Alzheimer's in Dish' Model Shows Promise for Accelerating Drug Discovery Nov. 27, 2024 — A decade ago ...

This class of drugs was associated with a 20% lower ... please read studies about vitamin D deficiency linked to Alzheimer’s and vascular dementia, and extra-virgin olive oil could boost brain ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...